Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
32.63
+0.57 (1.78%)
At close: Sep 18, 2025, 4:00 PM EDT
32.85
+0.22 (0.67%)
Pre-market: Sep 19, 2025, 7:46 AM EDT
HRMY Revenue
Harmony Biosciences Holdings had revenue of $200.49M in the quarter ending June 30, 2025, with 16.01% growth. This brings the company's revenue in the last twelve months to $772.53M, up 17.74% year-over-year. In the year 2024, Harmony Biosciences Holdings had annual revenue of $714.73M with 22.80% growth.
Revenue (ttm)
$772.53M
Revenue Growth
+17.74%
P/S Ratio
2.42
Revenue / Employee
$2,882,563
Employees
268
Market Cap
1.88B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 714.73M | 132.71M | 22.80% |
Dec 31, 2023 | 582.02M | 144.17M | 32.93% |
Dec 31, 2022 | 437.86M | 132.42M | 43.35% |
Dec 31, 2021 | 305.44M | 145.70M | 91.21% |
Dec 31, 2020 | 159.74M | 153.75M | 2,564.59% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
HRMY News
- 3 days ago - 11 fast-growing small-cap stocks that could get a boost from the Fed's next move - Market Watch
- 14 days ago - Harmony Biosciences Holdings, Inc. (HRMY) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 24 days ago - Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress - Business Wire
- 4 weeks ago - Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference - Business Wire
- 4 weeks ago - Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug - Seeking Alpha
- 6 weeks ago - Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 - Business Wire
- 2 months ago - Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 - Business Wire